...
search icon
cmrx-img

Chimerix Inc, Common Stock

CMRX

NMQ

$5.17

+$0.09

(1.77%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$465.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.73M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.34
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.75 L
$5.53 H
$5.17

About Chimerix Inc, Common Stock

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCMRXSectorS&P500
1-Week Return13.38%0.54%0.54%
1-Month Return34.64%3.28%1.66%
3-Month Return487.5%3.01%3.83%
6-Month Return387.74%-4.69%9.77%
1-Year Return323.77%1.41%23.47%
3-Year Return-5.83%15.72%42.73%
5-Year Return198.84%42.38%82.01%
10-Year Return-87.62%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue12.52M5.37M1.98M33.82M324.00K[{"date":"2019-12-31","value":37.01,"profit":true},{"date":"2020-12-31","value":15.88,"profit":true},{"date":"2021-12-31","value":5.85,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.96,"profit":true}]
Cost of Revenue38.49M36.23M468.00K447.00K1.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":94.13,"profit":true},{"date":"2021-12-31","value":1.22,"profit":true},{"date":"2022-12-31","value":1.16,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit(25.97M)5.37M1.51M33.38M324.00K[{"date":"2019-12-31","value":-77.81,"profit":false},{"date":"2020-12-31","value":16.09,"profit":true},{"date":"2021-12-31","value":4.53,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.97,"profit":true}]
Gross Margin(207.46%)100.00%76.35%98.68%100.00%[{"date":"2019-12-31","value":-207.46,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":76.35,"profit":true},{"date":"2022-12-31","value":98.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses63.46M49.89M92.49M93.76M93.39M[{"date":"2019-12-31","value":67.68,"profit":true},{"date":"2020-12-31","value":53.21,"profit":true},{"date":"2021-12-31","value":98.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.6,"profit":true}]
Operating Income13.54M(44.52M)(173.40M)(60.39M)(93.06M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-328.7,"profit":false},{"date":"2021-12-31","value":-1280.37,"profit":false},{"date":"2022-12-31","value":-445.88,"profit":false},{"date":"2023-12-31","value":-687.18,"profit":false}]
Total Non-Operating Income/Expense(122.71M)1.99M328.00K235.51M22.03M[{"date":"2019-12-31","value":-52.11,"profit":false},{"date":"2020-12-31","value":0.84,"profit":true},{"date":"2021-12-31","value":0.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.35,"profit":true}]
Pre-Tax Income(112.58M)(43.52M)(173.24M)172.20M(82.09M)[{"date":"2019-12-31","value":-65.37,"profit":false},{"date":"2020-12-31","value":-25.27,"profit":false},{"date":"2021-12-31","value":-100.6,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-47.67,"profit":false}]
Income Taxes61.07M(1.40M)82.56M36.00K(166.90K)[{"date":"2019-12-31","value":73.98,"profit":true},{"date":"2020-12-31","value":-1.69,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.04,"profit":true},{"date":"2023-12-31","value":-0.2,"profit":false}]
Income After Taxes(173.65M)(42.13M)(255.79M)172.17M(81.93M)[{"date":"2019-12-31","value":-100.86,"profit":false},{"date":"2020-12-31","value":-24.47,"profit":false},{"date":"2021-12-31","value":-148.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-47.59,"profit":false}]
Income From Continuous Operations(112.58M)(43.52M)(173.24M)172.17M(84.89M)[{"date":"2019-12-31","value":-65.39,"profit":false},{"date":"2020-12-31","value":-25.28,"profit":false},{"date":"2021-12-31","value":-100.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-49.31,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(173.65M)(42.13M)(255.79M)172.17M(82.09M)[{"date":"2019-12-31","value":-100.86,"profit":false},{"date":"2020-12-31","value":-24.47,"profit":false},{"date":"2021-12-31","value":-148.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-47.68,"profit":false}]
EPS (Diluted)(0.91)(0.70)(2.08)1.96(0.92)[{"date":"2019-12-31","value":-46.43,"profit":false},{"date":"2020-12-31","value":-35.71,"profit":false},{"date":"2021-12-31","value":-106.12,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-46.94,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CMRX
Cash Ratio 6.12
Current Ratio 6.33

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CMRX
ROA (LTM) -30.22%
ROE (LTM) -48.59%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CMRX
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CMRX
Trailing PE NM
Forward PE 1.21
P/S (TTM) 2733.15
P/B 3.20
Price/FCF NM
EV/R 1880.41
EV/Ebitda 1.03
PEG NM

FAQs

What is Chimerix Inc share price today?

Chimerix Inc (CMRX) share price today is $5.17

Can Indians buy Chimerix Inc shares?

Yes, Indians can buy shares of Chimerix Inc (CMRX) on Vested. To buy Chimerix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CMRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Chimerix Inc be purchased?

Yes, you can purchase fractional shares of Chimerix Inc (CMRX) via the Vested app. You can start investing in Chimerix Inc (CMRX) with a minimum investment of $1.

How to invest in Chimerix Inc shares from India?

You can invest in shares of Chimerix Inc (CMRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in CMRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Chimerix Inc shares
What is Chimerix Inc 52-week high and low stock price?

The 52-week high price of Chimerix Inc (CMRX) is $5.53. The 52-week low price of Chimerix Inc (CMRX) is $0.75.

What is Chimerix Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Chimerix Inc (CMRX) is 3.20

What is the Market Cap of Chimerix Inc?

The market capitalization of Chimerix Inc (CMRX) is $465.16M

What is Chimerix Inc’s stock symbol?

The stock symbol (or ticker) of Chimerix Inc is CMRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top